- Home
- MAC vs LNTH Comparison
MAC vs LNTH Comparison
Compare MAC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MAC | LNTH |
|---|---|---|
| Founded | 1964 | 1956 |
| Country | United States | United States |
| Employees | 2845 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 6.5B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MAC | LNTH |
|---|---|---|
| Price | $22.97 | $99.70 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 10 |
| Target Price | $26.63 | ★ $106.99 |
| AVG Volume (30 Days) | ★ 2.8M | 868.0K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.94% | N/A |
| EPS Growth | ★ 11.36 | N/A |
| EPS | N/A | ★ 2.91 |
| Revenue | ★ $1,013,983,000.00 | $343,374,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.98 | $12.19 |
| P/E Ratio | ★ N/A | $34.36 |
| Revenue Growth | ★ 10.43 | 3.62 |
| 52 Week Low | $16.03 | $50.16 |
| 52 Week High | $26.68 | $111.86 |
Technical Indicators
Market Signals| Indicator | MAC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 52.54 | 44.06 |
| Support Level | $22.86 | $98.81 |
| Resistance Level | $25.97 | $100.40 |
| Average True Range (ATR) | 0.50 | 0.34 |
| MACD | 0.10 | 0.05 |
| Stochastic Oscillator | 70.13 | 55.50 |
Price Performance
Historical ComparisonAbout MAC Macerich Company (The)
Macerich invests in premium mall assets. The company owns 27 regional malls in its consolidated portfolio and 10 regional malls in its unconsolidated portfolio along with a power center and six other real estate assets. The company's total portfolio has 39.2 million square feet of gross leasable area and averaged $899 sales per square foot over the 12 months ended in March 2026.
About LNTH Lantheus Holdings Inc.
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.